Chemical engineering duo reviews plant-derived compounds delivered via nanoparticles for ED — heavy on preclinical data, light on clinical evidence
Journal: Asian Journal of Andrology | Published: 2026-03-24 | Type: Review | PMID: 41873566 Authors: Bhaskar Rakesh, Han Sung Soo (School of Chemical Engineering, Yeungnam University, South Korea) Funding/COI: Neither disclosed
Two chemical engineers review the case for delivering phytochemicals — plant-derived compounds like antioxidants and PDE5 modulators — via nanocarriers (liposomes, nanoemulsions, dendrimers) to penile smooth muscle tissue. The core argument is that synthetic ED drugs have adverse effects and poor targeted delivery, and that plant compounds packaged in nanotech could do better. No original data is presented, no systematic search methodology is described, and no clinical effect sizes appear anywhere in the abstract.
This is a narrative review, not a systematic one. No search methodology is reported, no PRISMA flow diagram, no inclusion/exclusion criteria. The authors are chemical engineers — not urologists, andrologists, or pharmacologists — which is apparent in the framing: the paper is organized around drug delivery mechanisms rather than clinical outcomes. Without knowing which studies were selected and why, there is no way to evaluate whether the evidence base is representative or cherry-picked.
The abstract conflates preclinical (animal model) data with clinical evidence under the phrase "preclinical and clinical studies." This is a common rhetorical move that makes a thin clinical record look more substantial than it is.
Skip this one for clinical guidance. A narrative review by chemical engineers with no disclosed funding, no systematic search, and no clinical effect sizes tells you what the authors find interesting about drug delivery — not what works in humans with ED. The nanomedicine framing is intellectually legitimate, but "preclinical and clinical studies show promise" has been the holding pattern for plant-based ED compounds for two decades. Until a well-designed RCT tests a specific phytochemical-nanocarrier formulation against placebo in men with ED, this remains engineering speculation dressed in clinical language.